Lineage Cell Therapeutics

Quarterly Financials

Values in thousands2026-03-312025-12-312025-09-302025-06-30
Revenue
$1,725
$6,608
$3,681
$2,765
Gross Profit
1,537
6,542
3,676
2,726
EBITDA
-7,405
-6,362
-29,574
-4,769
EBIT
-7,593
-6,548
-29,752
-4,940
Net Income
-4,812
851
-29,781
-30,464
Net Change In Cash
1,725
6,608
3,681
2,765
Free Cash Flow
-8,132
-4,989
-3,628
-5,553
Cash
35,939
40,791
40,463
42,271
Basic Shares
261,175
230,116
228,853
228,356

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$14,556
$9,499
$8,945
$14,703
Gross Profit
13,711
9,165
8,274
13,975
EBITDA
-21,080
-20,869
-24,041
-21,793
EBIT
-21,779
-21,478
-24,733
-22,520
Net Income
-63,533
-18,609
-21,486
-26,273
Net Change In Cash
14,556
9,499
8,945
14,703
Cost of Revenue
-43,468
Free Cash Flow
-19,441
-23,657
-29,240
646
Cash
40,791
45,789
35,442
11,355
Basic Shares
230,116
200,193
172,663
169,792

Earnings Calls

QuarterEPS
2026-03-31
-$0.02
2025-12-31
$0.003
2025-09-30
-$0.13
2025-06-30
-$0.13